Re: New Drug evolving for T315I

[Guest guest]

Exciting - but I noticed a reference to the company making an application for

this drug  in 2008.  Did I miss something?

From: Lottie Duthu <lotajam@...>

Subject: [ ] New Drug evolving for T315I

" CML " < >

Date: Wednesday, September 16, 2009, 1:10 AM

 

OHSU is developing a new drug for treating T315i. I am present here a portion

which was just published and if you are interested, you can follow up at this

link.

" A new drug candidate, SGX393, has been found to inhibit most resistant

mutations, including T315I, both in mouse models and in patient cells in

laboratory studies. SGX393 was identified by SGX Pharmaceuticals Inc., a

biotechnology company focusing on cancer therapeutics. The OHSU Cancer Institute

researchers took this a step further.

" Because none of the drugs controlled all of the known mutations, we extended

our study to look at using combinations of the drugs, " said Eide,

research technician, hematology/medical oncology, OHSU School of Medicine.

" Remarkably, we found that the combination of SGX393 with either Sprycel or

Tasigna completely suppressed resistant growth. Our findings raise the exciting

possibility that inhibitor 'cocktails' may be sufficient to completely pre-empt

drug resistance in CML, " Eide said. He is a co-author with OHSU Cancer Institute

research scientist O'Hare, Ph.D., research specialist, hematology/medical

oncology, OHSU School of Medicine. The study was performed in the laboratory of

Deininger, M.D., Ph.D., associate professor of medicine,

hematology/medical oncology, OHSU School of Medicine.

" What patients should know is that, with the addition of this drug candidate to

the currently available set of clinical CML drugs, we may have the therapeutic

tools to achieve and maintain even more effective and longer control of their

disease, " Bumm said.

" Gleevec continues to be remarkably successful in the vast majority of patients.

However, for those patients who develop resistance, incorporating a targeted

T315I inhibitor such as SGX393 into the suite of available CML drugs in the

clinic is urgently needed. This is not equivalent to cure, but it could

potentially represent an important advance in disease management with CML

inhibitor therapy.

SGX Pharmaceuticals, Inc. is targeting submitting an Investigational New Drug

application for SGX393 in the first half of 2008. OHSU has licensed some of the

underlying technology used in this research to MolecularMD.

------------ --------- -------

Article adapted by Medical News Today from original press release.

------------ --------- -------

" The OHSU Cancer Institute is the only National Cancer Institute-designate d

center between Sacramento and Seattle. It comprises some 120 clinical

researchers, basic scientists and population scientists who work together to

translate scientific discoveries into longer and better lives for Oregon's

cancer patients. In the lab, basic scientists examine cancer cells and normal

cells to uncover molecular abnormalities that cause the disease. This basic

science informs more than 200 clinical trials conducted at the OHSU Cancer

Institute. "

Source: Decker

Oregon Health & Science University

____________ _________ _________ _____

This article is from Science Daily on ABL Kinase Mutation Analysis for Gleevec

Resistance.

http://www.genpathd iagnostics. com/node/ 141?gclid= CMGq8_mt9ZwCFURR 2godT311ag

FYI,

Lottie Duthu